Vimarsana
Biggest News Aggregation in the World

Pfizer Ventures News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pfizer Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pfizer Ventures Today - Breaking & Trending Today

Advanced autoclave technology supports pioneering genetic research at Oxford Science Park - Vimarsana News

Advanced autoclave technology supports pioneering genetic research at Oxford Science Park

Nucleome Therapeutics, a leading UK biotech firm that specialises in decoding the dark genome's non-coding DNA regions to develop precision medicines for autoimmune diseases like multiple sclerosis, lupus, and rheumatoid arthritis, purchase LTE research-grade autoclave to assist with research. Click to read more...

HBM Healthcare Investments : Invitation to Ordinary Shareholders' Meeting of 17.06.2024 - Vimarsana News

HBM Healthcare Investments : Invitation to Ordinary Shareholders' Meeting of 17.06.2024

HBM Healthcare Investments Ltd Bundesplatz 1, 6300 Zug Invitation to the 23rd Ordinary Shareholders' Meeting Monday,...

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024 - Vimarsana News

STORM Therapeutics to Present Interim Phase 1 Clinical Data on its METTL3 RNA Methyltransferase Inhibitor STC-15 at ASCO 2024

STC-15 is the first METTL3 inhibitor to enter clinical development Clinical data will include safety, pharmacology, target modulation, and clinical activity CAMBRIDGE, England, May

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology - Vimarsana News

Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology

/PRNewswire/ -- Grey Wolf Therapeutics ("Grey Wolf" or "the company"), a clinical-stage biotechnology company leveraging first-of-its-kind antigen modulation...

Grey Wolf Therapeutics Closes $50M Series B Financing Expansion - Vimarsana News

Grey Wolf Therapeutics Closes $50M Series B Financing Expansion

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!